1Department of Pediatrics, Emory University School of Medicine, Children’s Healthcare of Atlanta at Egleston, Atlanta, GA.
2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
3Department of Pediatrics, Baylor College of Medicine, Children’s Hospital of San Antonio, San Antonio, TX.
4Department of Pediatrics, Case Western Reserve University, Rainbow Babies’ and Children’s Hospital, Cleveland, OH.
5Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX.
6Department of Pediatrics, University of Minnesota, Minneapolis, MN.
*See also p. 1179.
Drs. Grunwell and Kamat conceived and developed the study and wrote the article. Drs. Travers and McCracken conducted statistical analyses and edited the article. Drs. Scherrer, Stormorken, Chumpitazi, Roback, and Stockwell edited the article. All authors read and approved the article.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal).
Dr. Grunwell is supported by a T32GM095442. Dr. Scherrer disclosed off-label product use: although commonly utilized in pediatric procedural sedation, ketamine is not currently FDA approved for use in children. Dr. Chumpitazi disclosed off-label product use: ketamine/sedation. Dr. Roback disclosed off-label product use: the manuscript is about ketamine, which is commonly used for pediatric sedation, but is not FDA approved for children for this indication. Dr. Stockwell received funding from Finley Law (expert witness) and from Dan Warlick, attorney (expert witness). The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]
